FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials. PMID 40196369 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease. PMID 40190340 · Gastro Hep Adv · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sijunzi decoction granules for the treatment of advanced refractory colorectal cancer: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. PMID 40182845 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II/III trial of rosuvastatin with neoadjuvant chemo-radiation in patients with locally advanced rectal cancer. PMID 40177244 · Front Oncol · 2025 The record describes a protocol for a randomized phase II/III trial with a drug intervention and time-to-event endpoints, but it does not report any actual trial results (e.g., survival data, hazard ratios). Therefore, it is not an eligible 'original formal-result report'. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. PMID 40165940 · J Pain Res · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Rikkunshito on Chemotherapy-Induced Nausea and Vomiting in Patients With Uterine Corpus or Cervical Cancer Treated With Cisplatin-Based Regimen-Placebo-controlled, Double-Blind, Randomized Confirmatory Study (JORTC-KMP03). PMID 40156342 · Integr Cancer Ther · 2025 The trial is a randomized, placebo-controlled study in oncology patients with a drug intervention (Rikkunshito) and reports original results. However, the primary endpoint is complete response (CINV), a categorical efficacy endpoint, not a time-to-event endpoint (e.g., OS, PFS, DFS, TTP). The study also does not explicitly report being Phase III or a definitive trial, and the abstract does not mention Phase information. Therefore, it fails the required time-to-event efficacy endpoint criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of honey-ginger mouthwash on oral mucositis in patients undergoing chemotherapy. PMID 40134126 · J Immunoassay Immunochem · 2025 The study is a randomized Phase III trial in oncology patients, but the intervention is a honey-ginger mouthwash for prevention of chemotherapy-induced oral mucositis (a supportive care/symptomatic intervention), not a drug-containing anticancer therapy. The primary endpoints are oral mucositis severity scores and pain intensity, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet the required criteria for inclusion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab. PMID 40124649 · Explor Target Antitumor Ther · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Reading Performance in Geographic Atrophy: Comparison of Different Reading Speed Measures for Capturing Longitudinal Changes. PMID 40124312 · Ophthalmol Sci · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific. PMID 40120920 · Travel Med Infect Dis · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Timing of transcutaneous acupoint electrical stimulation for postoperative recovery in geriatric patients with gastrointestinal tumors: study protocol for a randomized controlled trial. PMID 40109717 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis. PMID 40104212 · Rheumatol Adv Pract · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis. PMID 40094013 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Synthetic Versus Biologic Mesh for Complex Open Ventral Hernia Repair: 3-Year Follow-Up of a Pilot Randomized Controlled Trial. PMID 40071184 · HCA Healthc J Med · 2025 The study is a randomized controlled trial comparing biologic versus synthetic mesh for hernia repair, which is not an oncology study. It does not involve a drug-containing intervention, and the primary endpoint is major complications (infection, recurrence, reoperation, death), not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Conservative endometrioma surgery: The combined technique versus CO2-laser vaporization only (BLAST: Belgium LAser STudy): Clinical protocol for a multicenter randomized controlled trial. PMID 40048474 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. PMID 40043697 · Acta Haematol · 2025 未发现恶性肿瘤人群证据。 |
S
B
|
严格 v3 独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An overview of current phase 3 radiopharmaceutical therapy clinical trials. PMID 40041466 · Front Med (Lausanne) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical trial in cancer patients shows immune metabolic effects exerted by formulated bioactive phenolic diterpenes with potential clinical benefits. PMID 40034703 · Front Immunol · 2025 The study is a randomized controlled trial in cancer patients with a drug-like intervention (bioactive formula). However, it does not meet the core eligibility criteria: the trial phase is not specified as Phase III/IIIb or Phase II/III, and the primary readouts are immune-metabolic and inflammatory biomarkers, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier analysis or hazard ratio. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Are all programmed cell death protein 1 inhibitors the same? PMID 40027132 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The effect of intraoperative low-dose ketamine versus dexmedetomidine infusion on postoperative bowel recovery in patients undergoing gastrointestinal malignancy surgeries: Placebo-controlled, randomized trial. PMID 40026739 · J Anaesthesiol Clin Pharmacol · 2025 Study is a randomized trial in oncology patients but does not meet key eligibility criteria: primary endpoint is not a time-to-event oncology efficacy endpoint (OS/PFS/DFS etc.), and the drug interventions are supportive care agents, not oncology drugs. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial. PMID 40016875 · Curr Neuropharmacol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial. PMID 39991735 · Front Endocrinol (Lausanne) · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial. PMID 39985390 · Integr Cancer Ther · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial. PMID 39980188 · Pediatr Dermatol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials. PMID 39958346 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous Electrical Acupoint Stimulation Improves Postoperative Nutrition and Promotes Early Recovery of Gastrointestinal Function in Patients with Colorectal Cancer. PMID 39957303 · Comb Chem High Throughput Screen · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Curcumin Supplementation as a Preventive Strategy Against Tamoxifen-Induced Nonalcoholic Fatty Liver Disease in ER+ Breast Cancer Patients: A Triple-Blind Randomized Placebo-Controlled Trial. PMID 39948699 · J Diet Suppl · 2025 The trial is a randomized, placebo-controlled study in breast cancer patients, but the primary endpoint is the incidence of NAFLD grade change (a binary outcome), not a time-to-event endpoint. The study does not report OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios. The phase is not specified, and it does not meet the criteria for a definitive Phase III/IIIb or Phase II/III trial with a key time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR Outcomes trial. PMID 39939212 · J Clin Lipidol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Moderate Hypofractionated Post-Prostatectomy Radiotherapy (MYSTERY) Versus Conventionally Fractionated Post-Prostatectomy Radiotherapy (COPORT) for the Patients With Localized Prostate Cancer: The Protocol of a Prospective, Randomized Trial. PMID 39933701 · Cancer Control · 2025 The record is a protocol for a randomized controlled trial in oncology (prostate cancer) with time-to-event endpoints, but it is not an original formal-result report of a completed Phase III/IIIb or Phase II/III trial with a drug-containing intervention. It is a protocol document, and the intervention is radiotherapy-only, not a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acceptability and implementation potential of colorectal cancer screening and health literacy training: A qualitative study among general practitioners in deprived areas. PMID 39932910 · PLoS One · 2025 The record describes a qualitative study nested within a cluster-randomized controlled trial, focusing on acceptability and implementation of training for general practitioners. It does not report results of a randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (OS, PFS, etc.) from a Phase III or definitive Phase II/III study. The primary endpoint is qualitative acceptability, not an efficacy outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of GutGard® in Managing Gastroesophageal Reflux-Related Symptoms: A Phase III, Single-Centre, Double-Blind, Randomized Placebo-Controlled Trial. PMID 39929150 · Complement Med Res · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enarodustat for the Treatment of Anemia in Chinese Patients with Non-Dialysis Chronic Kidney Disease: A Phase 3 Trial. PMID 39927157 · Kidney Dis (Basel) · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis. PMID 39917064 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial. PMID 39909733 · Expert Rev Gastroenterol Hepatol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Recombinant Human Thrombopoietin (rhTPO) on Coagulation Function and Inflammatory Factors in the Treatment of Patients with Sepsis-Related Thrombocytopenia. PMID 39901742 · Clin Appl Thromb Hemost · 2025 The study is a randomized controlled trial of a drug (rhTPO) in humans, but it is not an oncology study. It investigates sepsis-associated thrombocytopenia, which is not a human malignant neoplasm. Furthermore, while mortality is reported, the study does not explicitly present a primary or key secondary time-to-event efficacy endpoint with Kaplan-Meier or hazard ratio analysis as required by the cohort definition. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies. PMID 39854278 · Chron Respir Dis · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE. PMID 39843293 · J Clin Lipidol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trial. PMID 39841658 · PLoS One · 2025 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis. PMID 39827864 · Int Arch Allergy Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation. PMID 39818248 · Asia Pac J Ophthalmol (Phila) · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of functional re-education and environmental adaptation in cancer patients with respiratory pathology: Study protocol. PMID 39787149 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effects of time-restricted eating on overweight and obese women with polycystic ovary syndrome: A randomized controlled trial study protocol. PMID 39787136 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of different educational interventions on cervical cancer knowledge and human papillomavirus vaccination uptake among young women in Japan: Preliminary results of a cluster randomized controlled trial. PMID 39774513 · PLoS One · 2025 The record describes a randomized trial in an oncology context (cervical cancer/HPV vaccination) but lacks a drug-containing intervention (vaccination is preventive, not a therapeutic drug for cancer) and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) for a cancer treatment. It is not a Phase III/IIIb or Phase II/III therapeutic trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. PMID 39774508 · PLoS One · 2025 Eligibility requires a drug-containing intervention and a specified definitive Phase III/IIIb or Phase II/III trial. The record describes a randomized trial of a biomarker test for screening, not a drug intervention. The trial phase is unclear from the provided metadata. Therefore, the record is excluded based on the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities. PMID 39720705 · Med Cannabis Cannabinoids · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation. PMID 39701047 · Dig Dis · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. PMID 39648106 · An Bras Dermatol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis. PMID 39647474 · Int Arch Allergy Immunol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. PMID 39605874 · Ophthalmol Sci · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study. PMID 39529307 · Pediatr Dermatol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |